Print Page  Close Window

Investor Overview

Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$8.45
Change (%)0.00 (0.00%)
Volume0
Data as of 01/17/18 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
01/16/18Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
01/08/18Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors
01/04/18Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
01/03/18Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
Upcoming EventsMore >>
DateTitle
02/12/18 3:00 p.m. ET
Eiger BioPharmaceuticals at the BIO CEO & Investor Conference
02/26/18
through
03/01/18
Eiger BioPharmaceuticals at the BTIG’s 5th Annual Healthcare Conference
04/08/18
through
04/10/18
Eiger BioPharmaceuticals at the H.C. Wainwright Global Biotechnology Conference
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.